Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 3/20 | 0.54 |
| ▸ | KIF5B | P33176 | 2/20 | 0.54 |
| ▸ | KDR | P35968 | 2/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | CCDC6 | Q16204 | 1/20 | 0.54 |
| ▸ | SRC | P12931 | 5/20 | 0.50 |
| ▸ | LCK | P06239 | 4/20 | 0.50 |
| ▸ | TEK | Q02763 | 3/20 | 0.50 |
| ▸ | HCK | P08631 | 1/20 | 0.50 |
| ▸ | RIPK2 | O43353 | 4/20 | 0.49 |
| ▸ | NEK7 | Q8TDX7 | 3/20 | 0.49 |
| ▸ | EIF2AK3 | Q9NZJ5 | 3/20 | 0.48 |
| ▸ | ABL1 | P00519 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | ABL2 | P42684 | 2/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.47 |
| ▸ | FLT1 | P17948 | 1/20 | 0.47 |
| ▸ | LTK | P29376 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6461270 | 0.95 | RET (0.53) | RETKIF5BKDRKCNH2CCDC6 | |
| SCHEMBL6867037 | 0.94 | SRC (0.53) | RETKIF5BKDRKCNH2CCDC6 | |
| SCHEMBL6865175 | 0.91 | KDR (0.52) | RETKIF5BKDRKCNH2CCDC6 | |
| SCHEMBL6460498 | 0.88 | RET (0.49) | RETKIF5BKDRKCNH2CCDC6 | |
| SCHEMBL6460272 | 0.85 | SRC (0.61) | RETKIF5BKDRKCNH2CCDC6 | |
| SCHEMBL6460851 | 0.85 | RIPK2 (0.60) | RETKIF5BKDRKCNH2CCDC6 | |
| SCHEMBL6467947 | 0.85 | RIPK2 (0.53) | RETKIF5BKDRKCNH2CCDC6 | |
| SCHEMBL6461293 | 0.84 | SRC (0.54) | RETKIF5BKDRKCNH2CCDC6 | |
| Carbamic Acid SCHEMBL7852916 | 0.84 | SRC (0.60) | RETKIF5BKDRKCNH2CCDC6 | |
| SCHEMBL6861029 | 0.84 | LCK (0.59) | KDRSRCLCKTEKHCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050008640-A1 | Method of treating transplant rejection | ABBOTT LABORATORIES | 2005-01-13 | — | — | US | disclosed |
| US-6713474-B2 | SERINE-THREONINE AND TYROSINE KINASE INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2004-03-30 | — | — | US | disclosed |
| US-20030153752-A1 | Pyrrolopyrimidines as therapeutic agents | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2003-08-14 | — | — | US | disclosed |
| EP-1114053-A1 | PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2001-07-11 | — | — | EP | disclosed |
| WO-2000017203-A1 | PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2000-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050008640-A1 | Method of treating transplant rejection | LCK, ZAP70, FYN | RET 2295/4885KIF5B 1241/4885KDR 3981/4885 |
| US-20030153752-A1 | Pyrrolopyrimidines as therapeutic agents | FLT1, FLT4, TFPI | RET 14/4885KIF5B 3080/4885KDR 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.